ICH E6(R3) is now final: what it means for trials in India

ICH E6(R3) is the new edition of the global guideline for good clinical practice (GCP). It is final, and it is already in effect in the EU and the US. This update explains what changed and how it reaches trials run in India. It ends with the steps sponsors and sites should take now.

What is ICH E6(R3), and when did it take effect?

The International Council for Harmonisation (ICH) adopted the final E6(R3) guideline on 6 January 2025. This first part has two pieces: the Principles and Annex 1. Regulators then brought it in on their own dates:

• European Union: in effect from 23 July 2025, according to the European Medicines Agency.
• United States: the FDA published its final guidance in the Federal Register on 9 September 2025.

A second part, Annex 2, covers newer designs. These include trials with decentralised elements and trials that use real-world data. ICH adopted Annex 2 in June 2026. It comes into effect in the EU on 15 January 2027. The FDA’s version of Annex 2 is still a draft.

What changes for sponsors and sites?

E6(R3) keeps the core of GCP: protect participants and produce results you can trust. What changes is how you get there. The guideline sets out 11 principles. Four shifts stand out.

• Quality by design. Teams build quality into the protocol from the start. They name the factors that are critical to quality before the trial begins.
• Effort that matches risk. Processes should fit the risk to participants and to the results. The guideline warns against needless burden on participants and investigators.
• Data governance. A new section in Annex 1 sets out what the investigator and the sponsor each own for data. It covers the full life of the data, from collection to archiving.
• Fit-for-purpose systems. Computerised systems must suit their use, and validation should follow the risk.

For most teams, this means fewer blanket checks and more thought up front. A monitoring plan should explain why it focuses where it does. A data plan should show who controls each step.

Where does India stand?

India has its own legal standard. The NDCT Rules, 2019 define “Good Clinical Practices Guidelines” in Rule 2(1)(p). They mean the guidelines CDSCO frames for clinical studies in India, adopted by the Drugs Technical Advisory Board.

CDSCO lists its GCP guidelines from 2017 on its website. It also lists draft GCP guidelines dated 12 September 2024. Until CDSCO finalises a new version, treat the current Indian guidelines as your legal baseline.

In practice, many trials in India also feed EU or US filings. Those trials need to meet E6(R3) today. The safest course is to meet both: the Indian rules for approval and conduct, and E6(R3) for the data you plan to use abroad. Our page on clinical trial approval under the NDCT Rules covers the Indian route.

A related change: CRO registration

A separate Indian rule took effect on 1 April 2025. Under new Rule 38A, a contract research organisation (CRO) cannot run a clinical trial or BA/BE study of a new or investigational drug without registration. The Central Licensing Authority grants it. A CRO applies on Form CT-07B through the SUGAM portal. The registration lasts five years. CDSCO’s CRO FAQs give the details.

What should you do now?

Start with these five steps:

1. Map the gaps. Compare your SOPs with the 11 principles and Annex 1.
2. Name what is critical to quality for each new protocol, and record why.
3. Make monitoring risk-based. Link each monitoring activity to a named risk.
4. Write down data ownership. Show who controls each system and each step.
5. Check your CRO. Confirm it holds CDSCO registration if your trial needs one.

Prequel can help with each step. Our quality assurance team runs GCP gap reviews and audits. Our clinical data management support covers data plans and system checks. Our site management and monitoring team builds risk-based monitoring plans. See all our work for the pharmaceuticals sector.